CAMP Stock Analysis: Buy, Sell, or Hold?
CAMP - CAMP4 Therapeutics Corporation Common Stock
$4.49
0.69 (18.16%)
â˛
5d:
+8.45%
30d:
+11.97%
90d:
+4.42%
WAIT
LOW Confidence
Analysis Updated: Sep 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CAMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CAMP is currently trading at $4.49, which is considered slightly high relative to its 30-day fair value range of $3.71 to $4.69.
Technical Outlook: Technically, CAMP is showing sideways momentum. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 18.2% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.92 (+120.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAMP is showing sideways momentum. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 18.2% recently.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.92 (+120.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.71 -
$4.69
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+18.2%)
- BULLISH: Trading 120.9% below Wall St target ($9.92)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.71 -
$4.69
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.70
Resistance Level
$4.60
Current Trend
Sideways
Technical data as of
Sep 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.65
Wall Street Target
$9.92
(+120.9%)
Revenue Growth (YoY)
18.8%
Share & Embed Analysis
Last updated: September 03, 2026 8:23 PM ET
Data refreshes hourly during market hours. Next update: 9:23 PM
Data refreshes hourly during market hours. Next update: 9:23 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 44 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 67 BUY |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 44 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$287 | 60 HOLD |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
12 analysts |
$138 | 63 BUY |
